Showing 4981-4990 of 5957 results for "".
- Pfizer Goes Solo on U.S. Shot Distribution, Opting Out of Government Channelshttps://modernod.com/news/pfizer-goes-solo-on-u-s-shot-distribution-opting-out-of-government-channels/2478499/Pfizer had already made it quite clear that it doesn’t need the U.S. government to help distribute its COVID-19 vaccine, should it be authorized by the FDA. Now it’s putting an exclamation point on that declaration, according to a FiercePharma
- Clots, Strokes And Rashes. Is COVID-19 A Disease Of The Blood Vessels?https://modernod.com/news/clots-strokes-and-rashes-is-covid-19-a-disease-of-the-blood-vessels/2478497/Whether it’s strange rashes on the toes or blood clots in the brain, the widespread ravages of COVID-19 have increasingly led researchers to focus on how the novel coronavirus sabotages the body’s blood vessels, according to an NPR
- Technique to Regenerate Optic Nerve Offers Hope for Future Glaucoma Treatmenthttps://modernod.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/Scientists have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, according to a Medical Xpress report. </
- What a Republican Senate Will Mean for the Health Care Industryhttps://modernod.com/news/what-a-republican-senate-will-mean-for-the-health-care-industry/2478493/Republicans appear likely to hold on slightly to their Senate majority after Tuesday’s elections, which could have a major impact on what healthcare legislation gets through Congress next year, according to a FierceHealthcare
- Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for Lytenava for Retinal Diseaseshttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-of-open-label-safety-study-for-lytenava-for-retinal-diseases/2478490/Outlook Therapeutics announced the completion of patient enrollment for its planned open-label safety study evaluating ONS-5010/Lytenava (NORSE THREE). Patient enrollment for the study was completed in less than 1 month, ahead of the planned 4-month enrollment schedule.
- Internal Documents Reveal COVID-19 Hospitalization Data The Government Keeps Hiddenhttps://modernod.com/news/internal-documents-reveal-covid-19-hospitalization-data-the-government-keeps-hidden/2478485/As coronavirus cases rise swiftly around the country, surpassing both the spring and summer surges, health officials brace for a coming wave of hospitalizations and deaths. Knowing which hospitals in which communities are reaching capacity could be key to an effective response to the growing cris
- Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy for Dry AMD Via Orbit SDShttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-received-investigational-gene-therapy-for-dry-amd-via-orbit-subretinal-delivery-system/2478480/Gyroscope Therapeutics announced that the first surgery using its proprietary Orbit Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been condu
- PolyActiva Appoints Tracy Valorie to its Board of Directorshttps://modernod.com/news/polyactiva-appoints-tracy-valorie-to-its-board-of-directors/2478481/PolyActiva announced the appointment of experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors. Ms. Valorie is recognized in the industry for her success in building and leading high performing teams a
- Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseaseshttps://modernod.com/news/ocumension-therapeutics-strengthens-pipeline-for-posterior-segment-eye-diseases/2478482/Ocumension Therapeutics announced that the company has entered into a collaboration and exclusive promotion agreement with Shandong Boan Biological Technology, a wholly-owned subsidiary of Luye Pharma Group, to jointly develop OT-702 (LY09004), a biosimilar to Eylea (aflibercept). Ocumension has
- Novartis Acquires Vedere Bio, Adding Novel Optogenetic Gene Therapy Technology for Treating Blindnesshttps://modernod.com/news/novartis-acquires-vedere-bio-adding-novel-optogenetic-gene-therapy-technology-for-treating-blindness/2478474/Novartis announced that it has acquired Vedere Bio, adding a new platform for AAV-based delivery of gene therapies and an optogenetics program. The acquisition will enable Novartis to advance its efforts to bring transformative therapies to a wide range of patients with blinding diseases.